Back to top
more

Sanofi (SNY)

(Real Time Quote from BATS)

$51.21 USD

51.21
1,345,013

-1.64 (-3.10%)

Updated Nov 6, 2024 11:54 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (59 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks News

Alnylam (ALNY) Q3 Loss Narrower than Expected, Revenues Rise

Alnylam Pharmaceuticals, Inc. (ALNY) reported a loss of $1.32 per share in the fourth quarter of 2016, narrower than both the Zacks Consensus Estimate loss of $1.35 and the year-ago loss of $1.07.

    Sanofi (SNY) Q4 Earnings In Line; Can Sell Praulent for Now

    Sanofi (SNY) reported fourth-quarter 2016 earnings of 67 cents per American depositary share, which was in line with the Zacks Consensus Estimate.

      Regeneron (REGN) Q4 Earnings: Will the Stock Disappoint?

      Regeneron Pharmaceuticals, Inc. (REGN) is scheduled to release fourth-quarter 2016 results on Feb 9, before the opening bell.

        Drug Stock Q4 Earnings to Watch on Feb 8: AGN, GSK & More

        How will these four drug stocks, AGN, GSK, ALNY and SNY, which are all scheduled to report Q4 results on Feb 8, fare this earnings season?

          Amgen (AMGN) Q4 Earnings Top; Repatha Positive in CV Study

          Amgen Inc. (AMGN) reported fourth-quarter 2016 earnings of $2.89 per share, beating the Zacks Consensus Estimate of $2.77 by 4.3% .

            Arpita Dutt headshot

            Pharma Stock Roundup: Pfizer, Merck, LLY Report Results, Teva Hit by Copaxone Ruling

            Key highlights this week include a court ruling in the Copaxone patent infringement lawsuit and earnings results from companies like Pfizer (PFE).

              SanofiRegeneron Sarilumab Approved in Canada for Arthritis

              Sanofi (SNY) and Regeneron Pharmaceuticals, Inc. (REGN) announced that their pipeline candidate, sarilumab, has been approved in Canada for the treatment of adult patients with moderate-to-severely active rheumatoid arthritis (RA).

                Will Amgen (AMGN) Keep the Earnings Streak Alive in Q4?

                We expect biotech major Amgen Inc. (AMGN) to beat expectations when it reports fourth-quarter 2016 and full-year results on Feb 2.

                  Sanofi Diabetes Drug Suliqua Wins EU Marketing Approval

                  Sanofi (SNY) announced that the European Commission has granted marketing authorization to its once-daily injection, Suliqua a combination of diabetes drugs Lantus and lixisenatide for the treatment of diabetes.

                    Key FDA Events to Watch Out for in Q1

                    Two important regulatory events scheduled in the first quarter of 2017.

                      Sanofi, ImmuNext Ink Deal, Focus on Autoimmune Diseases

                      Sanofi (SNY) announced an agreement with ImmuNext, Inc. for the development of a novel antibody to treat a range of autoimmune diseases including lupus and multiple sclerosis.

                        Amgen Inks Multiple Deals, Offers Update on Repatha Lawsuit

                        Amgen Inc. (AMGN) announced a new six-year sourcing and supply agreement with DaVita Inc. (DVA) to supply Epogen and Aranesp to meet the latter???s requirements.

                          Arpita Dutt headshot

                          The FDA Approved Fewer Drugs in 2016: Here's Why

                          Was there any specific reason for the significantly lower number of drug approvals in 2016 compared to 2015?

                            Impax (IPXL) Applies for Generic Aubagio; Sanofi Files Lawsuit

                            Impax Laboratories, Inc. (IPXL) announced that it has filed an Abbreviated New Drug application (ANDA) with the FDA for a generic version of Sanofi's Aubagio (teriflunomide) tablets, 14 mg.

                              Amgen's Repatha Wins Over Sanofi & Regeneron's Praluent

                              The U.S. District Court in Delaware granted Amgen, Inc. (AMGN) permanent injunction against infringement by Sanofi and Regeneron of two patents owned by the former for Repatha.

                                Arpita Dutt headshot

                                Pharma Stock Roundup: PCSK9 Inhibitor Praluent in News, Allergan's Preliminary 2017 View

                                Key highlights this week include a court injunction blocking sales of PCSK9 inhibitor Praluent and preliminary guidance from Allergan (AGN).

                                  Eli Lilly Acquires Boehringer Ingelheim's Pet Vaccines Unit

                                  Eli Lilly and Company's (LLY) animal health subsidiary Elanco, announced that it has closed the previously announced acquisition of German drugmaker Boehringer Ingelheim's Vetmedica U.S. pet vaccines unit.

                                    Sanofi (SNY) Closes Business Exchange Deal with Boehringer

                                    Sanofi (SNY) announced the closing of a previously announced deal to exchange its Merial animal health business with Boehringer Ingelheim's consumer healthcare (CHC) segment. The transaction was signed in Jun 2016.

                                      VIVUS (VVUS): Will Qsymia & Stendra Sales Improve in 2017?

                                      On Jan 3, we issued an updated report on VIVUS, Inc. (VVUS).

                                        Arpita Dutt headshot

                                        Regeneron vs. Vertex: Which Stock is a Better Pick?

                                        Both Regeneron (REGN) and Vertex look set for a rebound in 2017 after a tough and challenging 2016.

                                          J&J Resumes Talks with Actelion: Did Sanofi Just Lose Out?

                                          In an interesting turn of events, Johnson & Johnson (JNJ) announced that it is once again discussing a possible transaction with Swiss biotechnology company Actelion Ltd. (ALIOF).

                                            Arpita Dutt headshot

                                            Pharma Stock Roundup: Lilly Up on Guidance, Merck Awarded $2.54B in HCV Case

                                            Lilly (LLY) was among the biggest gainers among major pharma stocks last week with the company providing better-than-expected guidance for 2017.

                                              Lilly Stock Surges on Robust 2017 View; Launches Basaglar

                                              Eli Lilly and Company (LLY) issued a better-than-expected financial guidance for 2017, alleviating investor concern to a large extent.

                                                J&J (JNJ) Ends Deal Talks with Actelion: Will Sanofi Gain?

                                                On Tuesday, Johnson & Johnson (JNJ) announced that it has ended talks regarding a possible transaction with Swiss biotechnology company, Actelion Ltd. (ALIOF), reportedly for a disagreement over the purchase price.

                                                  Arpita Dutt headshot

                                                  Pharma Stock Roundup: Drug Pricing Heat Back on Sector, Endo, Mylan, AZN to Cut Jobs

                                                  Drug pricing is back in focus with president-elect Trump making it clear that he does not like price increases.